Psoriatic Arthritis News and Research

RSS
Like rheumatoid arthritis (RA), psoriatic arthritis is a chronic inflammatory disease of the joints and connective tissue. The disease causes joint pain and swelling that can lead to crippling along with inflamed and irritated scaly red patches of skin throughout the body. It is a progressive and debilitating disease and because there are no treatments specifically approved for psoriatic arthritis, doctors often use therapies approved for RA, including nonsteroidal anti-inflammatory drugs (NSAIDs) and disease modifying anti-rheumatic drugs (DMARDs). However, no DMARDs are currently approved for use in psoriatic arthritis. There are approximately 300,000 patients with psoriatic arthritis in the United States and the disease affects both men and women most commonly between the ages 30 and 50. Psoriatic arthritis patients are generally treated by rheumatologists and dermatologists.
RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

Scientists discover a key starting point for inhibiting inflammation in psoriasis and psoriatic arthritis

Scientists discover a key starting point for inhibiting inflammation in psoriasis and psoriatic arthritis

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

Risk of severe COVID-19 in adults with immune-mediated inflammatory diseases and those on immune-modifying therapies

Risk of severe COVID-19 in adults with immune-mediated inflammatory diseases and those on immune-modifying therapies

New AI tool can speed up the diagnosis of psoriatic arthritis by up to 4 years

New AI tool can speed up the diagnosis of psoriatic arthritis by up to 4 years

NYU Langone joins NIH-sponsored program as leading center to discover new targets for autoimmune, inflammatory diseases

NYU Langone joins NIH-sponsored program as leading center to discover new targets for autoimmune, inflammatory diseases

Updated guideline released for managing antirheumatic drugs in patients undergoing hip or knee replacement

Updated guideline released for managing antirheumatic drugs in patients undergoing hip or knee replacement

The impact of COVID-19 on people with systemic autoimmune rheumatic diseases

The impact of COVID-19 on people with systemic autoimmune rheumatic diseases

HSS study provides insight into real-world medication use for treatment of psoriatic arthritis

HSS study provides insight into real-world medication use for treatment of psoriatic arthritis

Study shows significant decreases in infections among people with psoriatic arthritis

Study shows significant decreases in infections among people with psoriatic arthritis

Researchers identify mechanism behind insufficient treatment efficacy of psoriasis drugs

Researchers identify mechanism behind insufficient treatment efficacy of psoriasis drugs

Real-world data sheds new light on biologic treatment and vaccine hesitancy in psoriasis patients

Real-world data sheds new light on biologic treatment and vaccine hesitancy in psoriasis patients

Immune-mediated inflammatory disease may increase risk of severe COVID-19 outcomes

Immune-mediated inflammatory disease may increase risk of severe COVID-19 outcomes

New clinical trial to test third dose of COVID-19 vaccine for immunocompromised people

New clinical trial to test third dose of COVID-19 vaccine for immunocompromised people

Investigational treatment improves survival rate of babies lacking thymus

Investigational treatment improves survival rate of babies lacking thymus

EULAR Patient Research Partners join in new research project to advance treatment of psoriatic arthritis

EULAR Patient Research Partners join in new research project to advance treatment of psoriatic arthritis

Exploring young people’s perspectives on patient-reported outcome measures in inflammatory arthritis

Exploring young people’s perspectives on patient-reported outcome measures in inflammatory arthritis

Switching to a balanced diet restores gut health and suppresses skin inflammation

Switching to a balanced diet restores gut health and suppresses skin inflammation

Passive smoking and air pollution associated with arthritis risk, poor response to RA treatment

Passive smoking and air pollution associated with arthritis risk, poor response to RA treatment